Ardelyx (ARDX) Competitors $4.30 +0.11 (+2.51%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$4.30 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. MRUS, ACLX, ACAD, SWTX, RARE, AAPG, PTGX, RNA, SRRK, and MLTXShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), Avidity Biosciences (RNA), Scholar Rock (SRRK), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Merus Arcellx ACADIA Pharmaceuticals SpringWorks Therapeutics Ultragenyx Pharmaceutical Ascentage Pharma Group International Protagonist Therapeutics Avidity Biosciences Scholar Rock MoonLake Immunotherapeutics Merus (NASDAQ:MRUS) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment. Do institutionals and insiders have more ownership in MRUS or ARDX? 96.1% of Merus shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 4.6% of Merus shares are owned by company insiders. Comparatively, 4.8% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is MRUS or ARDX more profitable? Ardelyx has a net margin of -14.86% compared to Merus' net margin of -506.73%. Ardelyx's return on equity of -34.45% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Merus-506.73% -35.99% -29.83% Ardelyx -14.86%-34.45%-13.81% Which has stronger valuation and earnings, MRUS or ARDX? Ardelyx has higher revenue and earnings than Merus. Ardelyx is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$36.13M103.13-$215.33M-$4.08-13.20Ardelyx$333.61M3.08-$39.14M-$0.22-19.52 Does the media refer more to MRUS or ARDX? In the previous week, Ardelyx had 4 more articles in the media than Merus. MarketBeat recorded 7 mentions for Ardelyx and 3 mentions for Merus. Merus' average media sentiment score of 0.56 beat Ardelyx's score of 0.38 indicating that Merus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend MRUS or ARDX? Merus presently has a consensus price target of $84.64, suggesting a potential upside of 57.20%. Ardelyx has a consensus price target of $10.89, suggesting a potential upside of 153.52%. Given Ardelyx's higher probable upside, analysts clearly believe Ardelyx is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, MRUS or ARDX? Merus has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Ardelyx has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. SummaryArdelyx beats Merus on 9 of the 17 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$2.43B$5.53B$9.05BDividend YieldN/A1.78%5.24%4.03%P/E Ratio-19.528.9827.5220.22Price / Sales3.08682.84421.02118.64Price / CashN/A158.5936.8958.07Price / Book5.884.588.045.67Net Income-$39.14M$31.34M$3.18B$249.13M7 Day Performance16.40%3.25%2.82%3.30%1 Month Performance16.40%6.80%3.70%5.20%1 Year Performance-19.27%1.89%35.41%21.38% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.3659 of 5 stars$4.30+2.5%$10.89+153.5%-19.3%$1.02B$333.61M-19.5290MRUSMerus1.8669 of 5 stars$52.60-0.7%$84.64+60.9%+1.7%$3.64B$54.73M-12.8937ACLXArcellx2.9715 of 5 stars$65.85+0.8%$111.23+68.9%+23.0%$3.63B$107.94M-22.0280Positive NewsACADACADIA Pharmaceuticals4.2577 of 5 stars$21.57-2.5%$27.88+29.2%+34.4%$3.61B$996.28M15.74510SWTXSpringWorks Therapeutics1.5261 of 5 stars$46.99+0.0%$52.57+11.9%N/A$3.54B$191.59M-13.78230Positive NewsRAREUltragenyx Pharmaceutical4.0621 of 5 stars$36.36-0.4%$87.00+139.3%-2.5%$3.44B$590.69M-6.181,294AAPGAscentage Pharma Group InternationalN/A$39.38-0.6%N/AN/A$3.43B$134.35M0.00600Gap UpPTGXProtagonist Therapeutics2.129 of 5 stars$55.27-0.8%$66.10+19.6%+48.4%$3.43B$434.43M73.69120RNAAvidity Biosciences2.186 of 5 stars$28.40-2.2%$65.59+130.9%-21.7%$3.42B$10.90M-9.47190SRRKScholar Rock3.3452 of 5 stars$35.42-1.1%$42.67+20.5%+355.0%$3.36B$33.19M-14.00140MLTXMoonLake Immunotherapeutics2.1799 of 5 stars$47.20-0.7%$74.50+57.8%+9.9%$3.02BN/A-20.522News Coverage Related Companies and Tools Related Companies MRUS Competitors ACLX Competitors ACAD Competitors SWTX Competitors RARE Competitors AAPG Competitors PTGX Competitors RNA Competitors SRRK Competitors MLTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
